Immune Biosolutions

Sipavibart could soon gain European approval for pre-exposure COVID-19 prophylaxis, its marketing application having recently been accepted, but AstraZeneca PLC ’s antibody will be a latecomer; sever

Cash is flooding into biopharmaceuticals, but regenerative medicine companies in particular have raked in large sums of cash – in part, because of the high upfront investment in manufacturing, but als